Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids.
A total of 14 patients (10 women and 4 men) ranging in age from 18 to 56 years who presented with active chronic noninfectious uveitis were treated with low-dose methotrexate (MTX). All patients had failed to respond to previous systemic corticosteroid therapy. MTX therapy was initiated in 8 patients at a dose of 40 mg given intravenously once weekly for 4 weeks followed by 15 mg/week given orally; 6 subjects were started on the oral regimen of 15 mg/week. During a follow-up period of 3-24 months, intraocular inflammation improved in all subjects under immunosuppressive therapy with MTX. A concomitant improvement in visual acuity was observed in 11 patients. Side effects included slight elevations in transaminases in 4 patients, transient mucositis in 1 case, partial alopecia in 2 subjects, and nausea in 3 patients. Our initial results suggest that low-dose MTX therapy may be considered as a therapeutic modality in noninfectious, steroid-refractory uveitis.